Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting

Recent advances have permitted successful therapeutic targeting of the immune system in head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets and agents are being rapidly adopted by the oncologic community and hold considerable promise. The National Cancer Institute spon...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2017-04, Vol.123 (7), p.1259-1271
Main Authors: Bauman, Julie E., Cohen, Ezra, Ferris, Robert L., Adelstein, David J., Brizel, David M., Ridge, John A., O'Sullivan, Brian, Burtness, Barbara A., Butterfield, Lisa H., Carson, William E., Disis, Mary L., Fox, Bernard A., Gajewski, Thomas F., Gillison, Maura L., Hodge, James W., Le, Quynh‐Thu, Raben, David, Strome, Scott E., Lynn, Jean, Malik, Shakun
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Biomarkers
Cancer
checkpoint inhibitors
Clinical trials
Clinical Trials as Topic
Combined Modality Therapy
Committees
Head
Head & neck cancer
head and neck cancer
Head and Neck Neoplasms - diagnosis
Head and Neck Neoplasms - etiology
Head and Neck Neoplasms - immunology
Head and Neck Neoplasms - therapy
Human papillomavirus
Humans
Immune system
Immunologic Factors - therapeutic use
Immunosurveillance
Immunotherapy
Immunotherapy - adverse effects
Immunotherapy - methods
Medical research
Metastases
Molecular Targeted Therapy
National Cancer Institute (U.S.)
Neoplasm Staging
Oncology
Patient Selection
Patients
Squamous cell carcinoma
Therapeutic targets
Treatment Outcome
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent advances have permitted successful therapeutic targeting of the immune system in head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets and agents are being rapidly adopted by the oncologic community and hold considerable promise. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issue of how to further investigate the use of immunotherapy in patients with HNSCC. The goals of the meeting were to consider phase 2 or 3 trial designs primarily in 3 different patient populations: those with previously untreated, human papillomavirus‐initiated oropharyngeal cancers; those with previously untreated, human papillomavirus‐negative HNSCC; and those with recurrent/metastatic HNSCC. In addition, a separate committee was formed to develop integrative biomarkers for the clinical trials. The meeting started with an overview of key immune components and principles related to HNSCC, including immunosurveillance and immune escape. Four clinical trial concepts were developed at the meeting integrating different immunotherapies with existing standards of care. These designs were presented for implementation by the head and neck committees of the National Cancer Institute‐funded National Clinical Trials Network. This article summarizes the proceedings of this Clinical Trials Planning Meeting, the purpose of which was to facilitate the rigorous development and design of randomized phase 2 and 3 immunotherapeutic trials in patients with HNSCC. Although reviews usually are published immediately after the meeting is held, this report is unique because there are now tangible clinical trial designs that have been funded and put into practice and the studies are being activated to accrual. Cancer 2017;123:1259–1271. © 2016 American Cancer Society. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issue of how to further investigate the use of immunotherapy in patients with head and neck squamous cell carcinoma. Although reviews usually are published immediately after the meeting is held, this report is unique because there are now tangible clinical trial designs that have been funded and put into practice and the studies currently are being activated to accrual.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.30449